Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
immunotherapy
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
abbvie
cancer immunotherapy
clinical trials
glaxosmithkline
merck
amgen
bristol-myers squibb
diagnostics
fda
gene therapy
gilead sciences
What
roundup
6
×
bio
drug
nash
new
news
patients
abbvie’s
according
acquisitions
advantages
ahead
akcea
albert
approval
bar
biggest
biofourmis
biogen’s
biopharma
biopharmaceutical
biotech
bourla
brings
bucks
cancer
car
cases
celebrate
celgene
centers
ceo
chance
cigarettes
colleagues
companies
company
control
convo
corner
Language
unset
unknown
Current search:
immunotherapy
×
roundup
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More